{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Mortality at 8 weeks was assessed for the 31 patients who were evaluated as part of the Primary Outcome Measure","groups":[{"description":"Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitabine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).\n\nVenetoclax: Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)\n\nDecitabine: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)","id":"OG000","title":"Decitabine/Venetoclax (Single Arm)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Mortality","type":"POST_HOC","unitOfMeasure":"Participants"}